We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2014 by Xinghui Liu, West China Second University Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01806454
First Posted: March 7, 2013
Last Update Posted: August 25, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Sichuan Academy of Medical Sciences
people's hospital of Guang'an
pengzhou shi fuyou baojianyuan
The first people's hospital of Neijiang
Suining Central Hospital
Sichuan Provincial Maternal and Child Health Care Hospital
Chengdu Women's and Children's Central Hospital
Information provided by (Responsible Party):
Xinghui Liu, West China Second University Hospital
March 1, 2013
March 7, 2013
August 25, 2015
October 2013
November 2015   (Final data collection date for primary outcome measure)
incidence of pre-eclampsia [ Time Frame: postpartum forty-two days ]
Same as current
Complete list of historical versions of study NCT01806454 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China
Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China: a Multi-center, Prospective Random Trial
the purpose of this study is to determine whether calcium supplementation is effective to prevent preeclampsia in Sichuang Province of china and which dose is more suitable
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Preeclampsia
Drug: calcium
  • Active Comparator: calcium A
    tablets, 600mg per day,till birth
    Intervention: Drug: calcium
  • Active Comparator: calcium B
    tablets,1200mg per day,till birth
    Intervention: Drug: calcium
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
11000
Not Provided
November 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Nulliparity;age ≥35 years;Previous pre-eclampsia;Family history of pre-eclampsia;Multiple pregnancy;Time between pregnancies ≥10years;Body mass index ≥25;diastolic pressure ≥ 80 mm Hg before 20 weeks' gestation;Proteinuria ≥+ on more than one occasion or ≥ 300 mg/24 h before 20 weeks' gestation;Underlying medical conditions(Pre-existing hypertension;Pre-existing renal disease;Pre-existing diabetes;Presence of antiphospholipid antibodies;Chronic autoimmune disease);male sex partner's predecessor wife has Previous pre-eclampsia

Exclusion Criteria:

  • first prenatal visit after 16 weeks' gestation;severe anemia;other Underlying medical conditions which need treatment first (such as uncontrolled hyperthyreosis )
Sexes Eligible for Study: Female
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01806454
hx2ck1
Not Provided
Not Provided
Not Provided
Xinghui Liu, West China Second University Hospital
West China Second University Hospital
  • Sichuan Academy of Medical Sciences
  • people's hospital of Guang'an
  • pengzhou shi fuyou baojianyuan
  • The first people's hospital of Neijiang
  • Suining Central Hospital
  • Sichuan Provincial Maternal and Child Health Care Hospital
  • Chengdu Women's and Children's Central Hospital
Not Provided
West China Second University Hospital
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP